Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

DA”) or European Medicines Agency
(“EMEA”);
• the safety and efficacy of the Company’s products or product candidates;
• the Company’s assessment of its clinical trials;
• the commencement and completion of clinical trials;
• the Company’s ability to develop, manufacture, license and sell its products or product
candidates;
• the Company’s ability to enter into and successfully execute license and collaborative
agreements, if any;
• the adequacy of the Company’s capital resources and cash flow projections, and the
Company’s ability to obtain sufficient financing to maintain the Company’s planned
operations;
• the adequacy of the Company’s patents and proprietary rights;
• the impact of litigation that has been brought against the Company and its officers and
directors and any proposed settlement of such litigation;
• the Company’s ability to regain compliance with the NASDAQ’s listing qualifications, or
its ability to successfully appeal the NASDAQ delisting; and
• the other risks described under Certain Risks and Uncertainties Related to the
Company’s Business, as contained in the Company’s Annual Report on Form 10-K and
Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a
number of factors that could cause actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the Company's Annual Report on Form
10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:
For Genta Incorporated
Tara Spiess/Andrea Romstad
TS Communications Group, LLC
(908) 286-3980
info@genta.c
'"/>





Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/5/2015)... , March 5, 2015 Vermillion, ... solutions company focused on gynecologic disease, announced today ... results before the market open on Wednesday, March ... and webcast at 8:30am Eastern. Conference Call & ... at 8:30am Eastern/5:30am Pacific Domestic: , 800-753-9057International: , ...
(Date:3/5/2015)...  As the pharmaceutical industry works to address ... professionals are placing a significant emphasis on company ... by LRN, the leader in Ethics & Compliance ... respondents expressed that clarity on company values is ... training programs (57%), trumping understanding of the PhRMA ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... March 30, 2011 Cempra Pharmaceuticals Inc. today announced ... president and chief executive officer, will present at the ... a.m. EDT, April 6, at The New York Palace ... officer of Cempra, will also be in attendance.  Dr. ...
... /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... of medical dressings, medical disposables and non-woven fabric ... today announced that Mr. Jianquan Li, Winner Medical,s ... with the Distinguished Contribution award for 2010 by ...
Cached Medicine Technology:Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences 2Winner Medical CEO Awarded and Appointed Position by CNITA 2Winner Medical CEO Awarded and Appointed Position by CNITA 3Winner Medical CEO Awarded and Appointed Position by CNITA 4
(Date:3/5/2015)... 05, 2015 Califia Farms , ... at Natural Products Expo West that its popular ready-to-drink ... percent soy and dairy free. Califia Farms Vegan Protein ... and are packed with six grams of an innovative ... fiber, B vitamins and magnesium. , Protein is an ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
(Date:3/5/2015)... March 05, 2015 As a ... (AAPA) review of Clearstream, LLC ’s products, ... Clearstream’s MediDefense line of products—led by their mPulse ... Affinity Partner Program. , The AAPA—which represents a ... all medical and surgical specialties in the U.S.—advocates ...
(Date:3/5/2015)... 05, 2015 The Journal of ... a special issue devoted entirely to ... PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococci) ... reaction triggered by infections such as strep throat, ... inflammation of the child's brain. This inflammation causes ...
(Date:3/5/2015)... March 05, 2015 Wimbledon Health ... provides vascular, echocardiogram and NCV testing, announced ... the Chief Medical Officer. Dr. Artel will be responsible ... of the WimbledonMED program and the continued growth and ... about working with Wimbledon Health Partners as a consulting ...
Breaking Medicine News(10 mins):Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3
... to relieve stress, a common cause of heart ... ... us think,of love and Valentine,s Day. This February, which also is National Heart,Awareness ... your heart. A healthy heart can be attained in a variety,of ways that ...
... PORTLAND, Ore. An Oregon Health & Science University Cancer ... the ability to predict if a mans prostate cancer is ... In order to make this discovery, researchers examined prostate cancer ... cancer patients. The researchers found that men whose tumors showed ...
... course of the presidential nomination campaign, some candidates health ... the phrase socialized medicine has been used to attack ... poll by the Harvard Opinion Research Program at the ... finds that Americans are split on whether a socialized ...
... National Board, KNOXVILLE, Tenn., Feb. 14 ... of Stacy Goldsholl, MD, as an,officer of its ... Medicine, is serving her second consecutive term as ... the premier medical society that,represents hospitalists. Hospital medicine ...
... (Nasdaq: DATA ), a technology company focused ... today reported that it will be,presenting at the ... at the Ritz Carlton in Laguna Niguel, California, ... on Wednesday afternoon,February 20th at 2:30 P.M., Pacific ...
... researchers from Europe and North America were given important ... national boundaries at a two-day training course in Croydon, ... Foundation as part of its Pan-European Clinical Trials (ECT) ... trials with a specific focus on the Euramos trial ...
Cached Medicine News:Health News:Healthy Heart, Healthy Home 2Health News:OHSU cancer institute researcher discovers new predictor of prostate cancer recurrence 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:Stacy Goldsholl, MD, Re-elected to Board of Society of Hospital Medicine 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 2Health News:DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference 3Health News:ESF's EMRC strengthens training course on clinical trials management 2
Consist of 6 disposable bevel blades (N0522) and chuck handle (0521). Malleable shafts. Designated most popular model or size....
Straight 9 mm downcutting Royce blade. Can be placed in closed handle for protection. Handle length folded 109 mm, 4.3 inches. Blade can be set automatically and rigidly at any point from straight to...
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
4 mm x 9 mm tip....
Medicine Products: